Search Follow us

EdisonTV

NeuroVive Pharmaceutical

EdisonTV | Pharmaceuticals & healthcare | 24/04/2018

Bitesize briefing - NeuroVive Pharmaceutical

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of the clinical presentation, low incidence rates and high unmet need make this an interesting area for specialist orphan drug developers. Here, healthcare analyst Dr Jonas Peciulis presents an overview of mitochondrial medicine, the competitive landscape in drug development and discusses one of the companies covered by Edison, specialising in the field, NeuroVive Pharmaceutical.

Read the report

Executive interview - Therapin

Executive interview - Therapin

THERAPiN is a global pharma-grade medical cannabis company that is based in Israel. It is a fully integrated firm, licensed for breeding, farming, manufacturing and distribution, which is creating high-end active ingredients for its own product development, as well as for sale to users in the medical, cosmetics and wellness space. THERAPiN intends to grow its business organically and through collaboration with partners globally.
Watch »

13/02/2020 |

Executive interview - Immunicum

Executive interview - Immunicum

Immunicum is a clinical-stage immunoncology company based in Stockholm, Sweden. The company is developing an allogeneic off-the-shelf dendritic cell immune activator (immune primer) for use in combination with tyrosine kinase inhibitors and checkpoint inhibitors in various solid tumour indications. In this video, the company’s chief operating officer, Sijme Zeilemaker, explains the recently announced updated data from the lead Phase II MERECA trial, which the company presented at the ASCO-SITC Clinical Immuno-Oncology Symposium on 6 February 2020.
Watch »

07/02/2020 | Immunicum

Executive interview - Cantargia

Executive interview - Cantargia

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in a Phase IIa clinical trial, CANFOUR, in solid tumours focusing on NSCLC and pancreatic cancer. Cantargia is also preparing to initiate a trial in the US. In this video, the company’s chief executive officer Göran Forsberg provides an overview of R&D progress, including a summary of the recently reported interim clinical trial results and expected newsflow.
Watch »

29/01/2020 | Cantargia

Executive interview - InMed: A leader in the development of cannabinol (CBN) therapeutics

Executive interview - InMed: A leader in the development of cannabinol (CBN) therapeutics

InMed is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases. InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.
Watch »

23/01/2020 | InMed Pharmaceuticals

Executive interview - Lavie Bio

Executive interview - Lavie Bio

Lavie Bio aims to improve food quality, sustainability and agricultural productivity through the introduction of microbiome-based ag-biological products. Using proprietary computational predictive technologies, Lavie Bio is implementing a ‘biology-driven design’ approach to introduce ‘next-generation’ bio-stimulants and bio-pesticides. The interview features CEO Ido Dor and board member Kristian Bjørneboe. Lavie Bio is a private subsidiary of Edison client Evogene (TASE: EVGN, NASDAQ: EVGN), a leading company in leveraging computational biology to design novel products for life science-based industries including human health, agriculture and industrial applications. To achieve its mission, Evogene established a unique Computational Predictive Biology (CPB) platform, leveraging the revolutions in big data and artificial intelligence, and incorporating a deep understanding of biology.
Watch »

14/01/2020 |

Executive interview - Abacus Health Products

Executive interview - Abacus Health Products

In this interview, Edison Analyst Max Jacobs discusses Abacus Health Products with Edison President Rachel Carroll after initiating on the company in the fourth quarter of 2019. Max touches on how Abacus differentiates itself amidst the noise in the CBD space. Max is a leading analyst and thought leader in the cannabis sector, having written multiple sector reports and moderated Edison’s cannabis conference in Israel in September 2019. Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. The company’s products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare, and are based on proprietary patent-pending technologies developed by Abacus. Abacus’s formulations combine advanced science with organic and natural ingredients to provide safe relief. The company currently offers two lines of products: CBD CLINIC marketed to the professional practitioner market, and CBDMEDIC marketed to the consumer market. Abacus’s products are offered across the US and are produced by a contract manufacturer in an FDA-registered and audited manufacturing facility.
Watch »

09/01/2020 | Abacus Health Products

Executive interview - Aptahem at DNB conference

Executive interview - Aptahem at DNB conference

Aptahem CEO Mikael Lindstam joined Edison at the DNB North American Life Science’s Conference to discuss highlights from 2019 and what to expect in 2020.
Watch »

19/12/2019 |

Executive interview - Cereno Scientific at DNB Conference

Executive interview - Cereno Scientific at DNB Conference

Cereno Scientific CEO Sten Sörensen joined Edison at the DNB North American Life Science’s Conference to discuss highlights from 2019 and what to expect in 2020.
Watch »

19/12/2019 |

Executive interview - Orexo at DNB Conference

Executive interview - Orexo at DNB Conference

Orexo US CEO Robert DeLuca joined Edison at the DNB North American Life Science’s Conference to discuss highlights from 2019 and what to expect in 2020.
Watch »

19/12/2019 | Orexo

Executive interview - Gentian at DNB conference

Executive interview - Gentian at DNB conference

Gentian CEO Hilja Ibert joined Edison at the DNB North American Life Science’s Conference to discuss highlights from 2019 and what to expect in 2020.
Watch »

19/12/2019 |

Executive interview - Brighter

Executive interview - Brighter

Brighter is a Swedish healthtech company focused on the development and commercialisation of self-monitoring and self-treatment health solutions for diabetes. Its lead product, Actiste, which recently received two CE marks, combines three critical components of daily diabetes management, a blood glucose meter, a lancet and an injection apparatus into one device with mobile connectivity to Brighter’s cloud-based service, the Benefit Loop. In this video the company discusses how Actiste integrates three essential steps for daily diabetes management in one device, decreasing the number of steps for daily treatment and measurement by up to 67%. The Actiste device is delivered as part of a subscription-based service that includes different levels of data sharing, continuous replenishment of everyday supplies delivered directly to the home and digital services designed to facilitate, improve and streamline the treatment. The company also discusses its cloud-based platform, the Benefit Loop, which collects, manages and analyses data for the purpose of sharing critical treatment information with friends, relatives, caregivers and healthcare providers to improve self-management outcomes.
Watch »

18/12/2019 | Brighter

Executive interview - BiondVax Pharmaceuticals

Executive interview - BiondVax Pharmaceuticals

BiondVax Pharmaceuticals (Nasdaq: BVXV) is a clinical biopharmaceutical company developing a universal flu vaccine, known as M-001. M-001 is currently undergoing a pivotal, clinical efficacy, Phase III trial in about 12,400 participants, the results of which are expected by the end of 2020. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains. In six completed clinical trials to date, the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains.
Watch »

17/12/2019 | BiondVax Pharmaceuticals

Executive interview - Expedeon at EKF 2019

Executive interview - Expedeon at EKF 2019

In this interview, Dr Heikki Lanckriet, CEO of Expedeon, provides an overview of the company. He discusses the key core products and markets for the company, the operational highlights in the year to date, and Expedeon’s financial position. He finishes the interview by explaining the upcoming catalysts that investors should pay attention to.
Watch »

09/12/2019 | Expedeon

Executive interview - Verona Pharma at EKF 2019

Executive interview - Verona Pharma at EKF 2019

In this interview, Dr David Ebsworth, non-executive chairman of Verona Pharma, provides an overview of the company and its pipeline of assets. He goes on to discuss plans for the pivotal Phase III development of ensifentrine, the company's lead product, as well as the regulatory and commercial strategy in Verona Pharma’s core markets. He finishes the interview by explaining how the company is funded and upcoming catalysts investors should pay attention to.
Watch »

09/12/2019 | Verona Pharma

Executive interview - Magforce at EKF 2019

Executive interview - Magforce at EKF 2019

In this interview, Dr Ben J Lipps, CEO of MagForce, provides an overview of the company and its NanoTherm treatment. He discusses how the technique has evolved since commercial brain tumour treatments have been available and how MagForce plans to broaden its reach in Europe, following the device’s first installation in Poland. He also shares his insight on the opportunities he sees for NanoTherm in the US and how the company is funded in the near term.
Watch »

09/12/2019 | MagForce

Executive interview - Abivax at EKF 2019

Executive interview - Abivax at EKF 2019

In this interview, Hartmut J Ehrlich, CEO, and Didier Blondel, CFO of Abivax, provide an overview of the business and the company’s pipeline. Hartmut explains the potential of ABX464, the company’s lead asset, as it is being tested in a range of diseases, including UC and HIV. Didier then explains how the company is funded and what upcoming catalysts investors should pay attention to.
Watch »

09/12/2019 | Abivax SA

Executive interview - Heidelberg Pharma at EKF 2019

Executive interview - Heidelberg Pharma at EKF 2019

In this interview, Dr Jan Schmidt-Brand, CEO of Heidelberg Pharma, provides an overview of the company and what differentiates its ATAC products from other ADC or CAR-Ts on the market. He also shares the company’s key partnerships and pipeline overview, the upcoming catalysts investors should pay attention to, and how the company is funded.
Watch »

06/12/2019 | Heidelberg Pharma

Executive interview - PAION at EKF 2019

Executive interview - PAION at EKF 2019

In this interview, Dr James Phillips, CEO of Paion, provides an overview of the company and its focus on anaesthesia products. He explains what differentiates remimazolam from other anaesthetics, how the established clinical data are perceived by key opinion leaders, and what key milestones investors should watch out for in the next 12–24 months. He also discusses how remimazolam is being commercialised in key markets and why the company decided to self-commercialise the drug in the EU.
Watch »

06/12/2019 | Paion

Executive interview - Avacta Group

Executive interview - Avacta Group

In this video, Alastair Smith, CEO of Avacta Group, discusses the progress the company has made this year. This includes new and expanded partnerships, operational and financial achievements, and the advancement of AVA6000 towards the clinic.
Watch »

05/12/2019 | Avacta Group

Executive interview - Kazia Therapeutics

Executive interview - Kazia Therapeutics

In this video, Kazia's CEO, Dr James Garner, explains the background to this interesting product which has a novel brain penetrating action which potentially could give it a unique role in the chronic treatment of glioblastoma. He discusses the latest trial data and the further development of the product in 2020.
Watch »

25/11/2019 | Kazia Therapeutics

Executive interview - Actinogen Medical

Executive interview - Actinogen Medical

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. In this video, the company’s chief executive officer Bill Ketelbey provides an update on recent developments, R&D progress and expected newsflow.
Watch »

22/11/2019 | Actinogen Medical